NASDAQ:MITO

Stealth BioTherapeutics Stock Forecast, Price & News

$1.79

+0.07 (+4.07 %)

(As of 01/22/2021 12:00 AM ET)

Add

Compare

Today's Range

$1.64

Now: $1.79▼

$1.88

50-Day Range

$1.30

MA: $1.48▼

$1.72

52-Week Range

$0.90

Now: $1.79▼

$5.00

Volume626,973 shs

Average Volume448,412 shs

Market Capitalization$93.30 million

P/E Ratio44.76

Dividend YieldN/A

Beta2.25

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases. The company's product candidates include SBT-20, a small peptide that targets and binds reversibly to cardiolipin, stabilizing mitochondrial structure, and function under conditions of oxidative stress; and SBT-272, a lead discovery pipeline compound, evaluating for rare neurodegenerative diseases, such as amyotrophic lateral sclerosis. Stealth BioTherapeutics Corp was founded in 2006 and is based in George Town, the Cayman Islands.

Overall MarketRank^™

1.27 out of 5 stars

Medical Sector

727th out of 1,925 stocks

Pharmaceutical Preparations Industry

365th out of 773 stocks

3.4 Analyst's Opinion

Consensus Rating
Stealth BioTherapeutics has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.00, Stealth BioTherapeutics has a forecasted upside of 346.9% from its current price of $1.79.
Amount of Analyst Coverage
Stealth BioTherapeutics has received no research coverage in the past 90 days.

2.3 Community Rank

Outperform Votes
Stealth BioTherapeutics has received 73 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Stealth BioTherapeutics has received 85 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Stealth BioTherapeutics has received 53.80% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Stealth BioTherapeutics and other stocks. Vote “Outperform” if you believe MITO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MITO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Stealth BioTherapeutics does not currently pay a dividend.
Dividend Growth
Stealth BioTherapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Stealth BioTherapeutics insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 1.19% of the stock of Stealth BioTherapeutics is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Stealth BioTherapeutics are expected to grow in the coming year, from ($0.09) to ($0.07) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Stealth BioTherapeutics is 44.76, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.30.
Price to Earnings Ratio vs. Sector
The P/E ratio of Stealth BioTherapeutics is 44.76, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 36.31.
Price to Book Value per Share Ratio
Stealth BioTherapeutics has a P/B Ratio of 3.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:MITO

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.stealthbt.com

Phone617-600-6888

Employees73

Debt

Debt-to-Equity RatioN/A

Current Ratio1.07

Quick Ratio1.07

Price-To-Earnings

Trailing P/E Ratio44.76

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$21.09 million

Price / Sales4.42

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.49 per share

Price / Book3.65

Profitability

EPS (Most Recent Fiscal Year)($1.72)

Net Income$-71,730,000.00

Net MarginsN/A

Return on Equity-421.89%

Return on Assets-100.33%

Miscellaneous

Outstanding Shares52,123,000

Market Cap$93.30 million

Next Earnings Date4/7/2021 (Estimated)

OptionableNot Optionable

$1.79

+0.07 (+4.07 %)

(As of 01/22/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive MITO News and Ratings via Email

Sign-up to receive the latest news and ratings for MITO and its competitors with MarketBeat's FREE daily newsletter.

Stealth BioTherapeutics (NASDAQ:MITO) Frequently Asked Questions

How has Stealth BioTherapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Stealth BioTherapeutics' stock was trading at $1.5887 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MITO shares have increased by 12.7% and is now trading at $1.79.
View which stocks have been most impacted by COVID-19.

Is Stealth BioTherapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stealth BioTherapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Stealth BioTherapeutics stock.
View analyst ratings for Stealth BioTherapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Stealth BioTherapeutics?

Wall Street analysts have given Stealth BioTherapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Stealth BioTherapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Stealth BioTherapeutics' CEO?

1,448 employees have rated Stealth BioTherapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Stealth BioTherapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Stealth BioTherapeutics' next earnings date?

Stealth BioTherapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, April 7th 2021.
View our earnings forecast for Stealth BioTherapeutics.

How were Stealth BioTherapeutics' earnings last quarter?

Stealth BioTherapeutics Corp (NASDAQ:MITO) released its quarterly earnings results on Thursday, November, 5th. The company reported ($0.02) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.02).
View Stealth BioTherapeutics' earnings history.

What price target have analysts set for MITO?

5 equities research analysts have issued twelve-month target prices for Stealth BioTherapeutics' shares. Their forecasts range from $4.00 to $10.00. On average, they expect Stealth BioTherapeutics' share price to reach $8.00 in the next year. This suggests a possible upside of 346.9% from the stock's current price.
View analysts' price targets for Stealth BioTherapeutics or view Wall Street analyst' top-rated stocks.

Who are some of Stealth BioTherapeutics' key competitors?

Some companies that are related to Stealth BioTherapeutics include Catalyst Pharmaceuticals (CPRX), Selecta Biosciences (SELB), Aeglea BioTherapeutics (AGLE), Immunic (IMUX), Trevena (TRVN), Arbutus Biopharma (ABUS), Axovant Sciences (AXON), Mustang Bio (MBIO), MEI Pharma (MEIP), Ampio Pharmaceuticals (AMPE), Fortress Biotech (FBIO), Concert Pharmaceuticals (CNCE), Cassava Sciences (SAVA), Verrica Pharmaceuticals (VRCA) and iBio (IBIO).
View all of MITO's competitors.

What other stocks do shareholders of Stealth BioTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stealth BioTherapeutics investors own include SCYNEXIS (SCYX), Allena Pharmaceuticals (ALNA), Acasti Pharma (ACST), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Miragen Therapeutics (MGEN), Matinas BioPharma (MTNB), Soleno Therapeutics (SLNO) and Arbutus Biopharma (ABUS).

Who are Stealth BioTherapeutics' key executives?

Stealth BioTherapeutics' management team includes the following people:

Ms. Irene P. McCarthy J.D., Pres ,CEO, Sec. & Director (Age 56)
Mr. Robert J. Weiskopf, Chief Financial Officer (Age 69)
Mr. Henry Hess, Chief Legal Counsel
Mr. Mike Malynn, VP of HR
Dr. Ben R. Bronstein, Chief Medical Officer (Age 70)
Dr. Brian D. Blakey, Chief Bus. Officer (Age 58)
Dr. W. Douglas Weaver, Chief Medical Officer
Mr. James R. Carr, Chief Clinical Devel. Officer (Age 57)

When did Stealth BioTherapeutics IPO?

(MITO) raised $81 million in an initial public offering on Friday, February 15th 2019. The company issued 6,200,000 shares at $12.00-$14.00 per share. Jefferies, Evercore ISI and BMO Capital Markets acted as the underwriters for the IPO and Nomura was co-manager.

What is Stealth BioTherapeutics' stock symbol?

Stealth BioTherapeutics trades on the NASDAQ under the ticker symbol "MITO."

How do I buy shares of Stealth BioTherapeutics?

Shares of MITO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Stealth BioTherapeutics' stock price today?

One share of MITO stock can currently be purchased for approximately $1.79.

How big of a company is Stealth BioTherapeutics?

Stealth BioTherapeutics has a market capitalization of $93.30 million and generates $21.09 million in revenue each year. The company earns $-71,730,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Stealth BioTherapeutics employs 73 workers across the globe.

What is Stealth BioTherapeutics' official website?

The official website for Stealth BioTherapeutics is www.stealthbt.com.

How can I contact Stealth BioTherapeutics?

Stealth BioTherapeutics' mailing address is 275 GROVE STREET SUITE 3-107, NEWTON MA, 02466. The company can be reached via phone at 617-600-6888 or via email at [email protected]

This page was last updated on 1/23/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here